Skip to main content
      RT @KDAO2011: What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had m

      TheDaoIndex KDAO2011

      3 years 10 months ago
      What's better, #cyclophosphamide or #rituximab in CT-ILD? The RECITAL Trial noted both work, but CYP had more GI side effects (not surprising). The study was just published in NEJM. QR code in image to view. #plenary abst#003 @rheumnow #ACR22 https://t.co/ZDIWtlc9dY
      RT @doctorRBC: Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high

      Robert B Chao, MD doctorRBC

      3 years 10 months ago
      Important to remember to screen for cancer in patients with idiopathic inflammatory myopathy, esp in high risk pts! Can even consider PET/CT, CT, pelvic US, initially. Question is... will insurances approve all of these tests? Abs#0002 @RheumNow #ACR22 https://t.co/uvr4jGVTFP
      RT @KDAO2011: Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Consensus for #cancer screening in IIM Presented: For more info, go to this session #CurbsideConsults #ACR22 @rheumnow #myositis https://t.co/vJ82rEX2wk
      RT @EBRheum: Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO

      Tagging off BLISS-LN, p

      Mike Putman EBRheum

      3 years 10 months ago
      Pooled data from belimumab RCTs w/>3,000 pts evaluating kidney outcomes vs PLBO Tagging off BLISS-LN, pooled analysis w/marginal but real benefit to adding BEL in pts with SLE I offer this to all pts w/SLE LN on MMF, but I do not push it #ACRbest #ACR22 @RheumNow #0352 https://t.co/QYGgB3ue36
      RT @KDAO2011: Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plena

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Consensus for #cancer screening in IIM Presented: When to Go Beyond Standard and Extended Screening #Plenary #ACR22 @rheumnow #myositis #ExpertOpinionNotData https://t.co/cL6zrMnzT3
      RT @drdavidliew: Cancer screening in myositis:
      the path has always been unclear and inconsistent

      Workable consensus rec

      David Liew drdavidliew

      3 years 10 months ago
      Cancer screening in myositis: the path has always been unclear and inconsistent Workable consensus recommendations @Dr_Alex_Oldroyd risk stratification but still extensive investigation burden for most now need to look at effectiveness including cost ABST0002 #ACR22 @RheumNow https://t.co/322qnGjB9K
      RT @Yuz6Yusof: #ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory

      Md Yuzaiful Md Yusof Yuz6Yusof

      3 years 10 months ago
      #ACR22 Abstr#0002 @Dr_Alex_Oldroyd presented eminence-based recommendation for patients with inflammatory myopathy. Enhanced screening for those high risk. Studies needed to assess feasibility i.e. cost, positive and negative predictive value of test etc. @RheumNow https://t.co/G1MyQDMhOa
      RT @KDAO2011: Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositi

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Consensus for #cancer screening in IIM Presented: How Often to Screen #Plenary #ACR22 @rheumnow #myositis https://t.co/h1kp7Z9ynO
      RT @KDAO2011: Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22
      @rhe

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Consensus for #cancer screening in IIM Presented: What tests to order for screening #Plenary #ACR22 @rheumnow #myositis https://t.co/pPLcsFLtG9
      RT @KDAO2011: Consensus for CA screening in IIM Presented: Risk factors to consider screening
      #Plenary #ACR22 @rheumnow

      TheDaoIndex KDAO2011

      3 years 10 months ago
      Consensus for CA screening in IIM Presented: Risk factors to consider screening #Plenary #ACR22 @rheumnow #myositis https://t.co/CDNPaRUpPS
      RT @JulianSegan: Risk stratification for cancer in myositis

      @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c

      Julian Segan JulianSegan

      3 years 10 months ago
      Risk stratification for cancer in myositis @RheumNow #ACR22 #Plenary https://t.co/j7R7P3PS7c
      RT @JulianSegan: Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk

      Julian Segan JulianSegan

      3 years 10 months ago
      Some suggested screening tests for malignancy in myositis. Recommendations based on assessment of risk factors @RheumNow #ACR22 #Plenary https://t.co/B0eASeo8hG
      RT @EBRheum: Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless!

      It's not flashy but

      Mike Putman EBRheum

      3 years 10 months ago
      Nice #SLE validation study. This kind of work is (1) time intensive and (2) thankless! It's not flashy but it winds up being the backbone/foundation for many subsequent studies Need more in other diseases, including sarcoidosis and myositis! @DidemSayginMD #ACR22 @RheumNow https://t.co/64z7DBFCnX
      RT @drdavidliew: GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA):

      initial 24w results disappointing (per

      David Liew drdavidliew

      3 years 10 months ago
      GUSTO 1y follow-up (TCZ +IVMPx3 but no ongoing PNL in new GCA): initial 24w results disappointing (permanent visual loss x1) BUT follow-up at 2y: control overwhelmingly maintained in responders We need to keep asking: can we use less PNL in GCA? When? ABST0470 #ACR22 @RheumNow https://t.co/smyw2nykO5 https://t.co/d2at0pJlSB
      RT @DrCassySims: Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow

      ⚠️safety data
      -Pancytopenia
      -Transaminitis
      -Dy

      Catherine Sims, MD DrCassySims

      3 years 10 months ago
      Xeljanz in PsA (@pfizer funded) #ACR22 @RheumNow ⚠️safety data -Pancytopenia -Transaminitis -Dyslipidemia -Elevated CPK without #myositis -Avoid in pregnancy and GI strictures 🤰Stop JAKi at least one month prior to conception🤰
      ×